Company intelligence / Profile preview
QUE Oncology
Melbourne, Victoria, Australiaqueoncology.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
QUE Oncology’s lead candidate, Q‑122, is an orally bioavailable small molecule currently in Phase 2 trials for the treatment of hot flashes in breast cancer survivors on endocrine therapy. The compound has demonstrated an excellent safety profile so far. The ongoing Phase 2 study spans clinical sites in the US, Australia, and New Zealand. Results were anticipated in 2020; however, no recent updates are available from the provided sources regarding trial completion or results.
- Therapeutic areas
- Women's HealthOncology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Brandon BioCatalyst
Beyond the preview
Go deeper on QUE Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QUE Oncology.